Skip to contentC
CNBX Pharmaceuticals Inc.
C
CNBXCNBX Pharmaceuticals Inc. Q1 2025 · 10-Q
Revenue$0.00$0.00−100.0% vs Q1 2024 Net Income-$34.35K-$34.35KN/M vs Q1 2024 EPS Diluted-$0.00-$0.00N/M vs Q1 2024 Operating Income-$36,837N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CNBX Pharmaceuticals Inc. · CIK 1343009 · Engraved from SEC EDGAR
ended Nov 30, 2024 · filed Jan 13, 2025 · 44 d after period end